Linezolid

Generic Name
Linezolid
Brand Names
Zyvox, Zyvoxam
Drug Type
Small Molecule
Chemical Formula
C16H20FN3O4
CAS Number
165800-03-3
Unique Ingredient Identifier
ISQ9I6J12J
Background

Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - ...

Indication

Linezolid is indicated in adults and children for the treatment of infections caused by susceptible Gram-positive bacteria, including nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, and vancomycin-resistant Enterococcus faecium infections. Examples of susceptible bacteria include Staphylococcus aureus, Streptococcus pn...

Associated Conditions
Community Acquired Pneumonia (CAP) caused by Staphylococcus Aureus Infections, Community acquired pneumonia caused by Susceptible strains of Streptococcus pneumoniae, Complicated Skin and Skin Structure Infection caused by Staphylococcus Aureus Infections, Complicated Skin and Skin Structure Infection caused by Streptococcus Agalactiae Infection, Complicated Skin and Skin Structure Infection caused by Streptococcus Pyogenes Infection, Nosocomial Pneumonia caused by Staphylococcus Aureus Infections, Nosocomial Pneumonia caused by Streptococcus Pneumoniae Infections, Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus Aureus Infections, Uncomplicated Skin and Skin Structure Infections caused by Streptococcus Pyogenes Infection, Vancomycin-resistant Enterococcus faecium infection
Associated Therapies
-

Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-03-06
Last Posted Date
2012-04-30
Lead Sponsor
Pfizer
Target Recruit Count
18
Registration Number
NCT01544673
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

First Posted Date
2011-08-22
Last Posted Date
2018-08-29
Lead Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Target Recruit Count
666
Registration Number
NCT01421511
Locations
🇷🇺

Trius investigator site 287, Barmaul, Russian Federation

🇿🇦

Trius investigator 451, Centurion, Gauteng, South Africa

🇿🇦

Trius investigator 449, Pretoria, Gauteng, South Africa

and more 108 locations

Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients

First Posted Date
2011-06-01
Last Posted Date
2012-05-22
Lead Sponsor
Pfizer
Target Recruit Count
7260
Registration Number
NCT01363271

A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections

First Posted Date
2011-01-26
Last Posted Date
2019-10-16
Lead Sponsor
Melinta Therapeutics, Inc.
Target Recruit Count
256
Registration Number
NCT01283581
Locations
🇺🇸

University of South Alabama Medical Center, Mobile, Alabama, United States

🇺🇸

Southbay Pharma Research, Buena Park, California, United States

🇺🇸

Drug Research and Analysis Corp, Montgomery, Alabama, United States

and more 22 locations

GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection

First Posted Date
2010-09-24
Last Posted Date
2017-12-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
84
Registration Number
NCT01209078
Locations
🇺🇸

GSK Investigational Site, West Reading, Pennsylvania, United States

Population Pharmacokinetics of Linezolid

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-09-13
Last Posted Date
2012-10-23
Lead Sponsor
University Hospital, Toulouse
Target Recruit Count
60
Registration Number
NCT01200654

TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

First Posted Date
2010-07-27
Last Posted Date
2018-08-29
Lead Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Target Recruit Count
667
Registration Number
NCT01170221
Locations
🇺🇸

Trius investigator site 135, Hialeah, Florida, United States

🇺🇸

Trius investigator site 133, Butte, Montana, United States

🇺🇸

Trius investigator site 120, Houston, Texas, United States

and more 81 locations

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

First Posted Date
2010-05-24
Last Posted Date
2011-12-16
Lead Sponsor
Furiex Pharmaceuticals, Inc
Target Recruit Count
161
Registration Number
NCT01128530
Locations
🇺🇸

Furiex Research Site, Webster, Texas, United States

Bioequivalence Study Comparing Linezolid 600 Mg Oral Suspension With 600 Mg Tablet In Chinese Healthy Male Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-01-26
Last Posted Date
2012-02-01
Lead Sponsor
Pfizer
Target Recruit Count
20
Registration Number
NCT01055769
Locations
🇨🇳

Pfizer Investigational Site, Shanghai, China

Cost Effectiveness Of Linezolid In Central America

Withdrawn
Conditions
Interventions
First Posted Date
2009-12-29
Last Posted Date
2012-03-02
Lead Sponsor
Pfizer
Registration Number
NCT01040585
© Copyright 2024. All Rights Reserved by MedPath